Schizophrenia Market Research Report: Information by Type (Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic Schizophrenia and Undifferentiated Schizophrenia), Treatment {Second-Generation Antipsychotics [Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone)], Third-Generation Antipsychotics and others}, Route of Administration (Oral and Injectables) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025Market HighlightsThe global Schizophrenia Market is expected to grow at a CAGR of 3.2% during the forecast period 2017-2023.Schizophrenia is a chronic and severe mental disorder that affects the thinking, feeling, and behavior of the person.
People with schizophrenia may be more in imagination world and lost touch with reality.
This is often due to physical illnesses, such as cardiovascular, metabolic and infectious diseases.
Moreover availability of funds and WHO initiative towards developing countries fuel the market in developing region.Regional AnalysisThe Americas dominate the global schizophrenia market owing to the presence of awareness of healthcare, high healthcare spending, and increasing government support for research & development.
Europe holds the second largest share of the global schizophrenia market as result of increasing focus of various government agencies on the treatment of mental illness disease such as schizophrenia.
Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development projected to drive the market in India, Iran, Pakistan, Tanzania, over the forecasted period.
Global Schizophrenia Drugs Market is expected to reach USD 7.9 billion by 2022.
Antipsychotic drugs are mainly prescribed, as they help to control symptoms like disorganized thinking, hallucinations, and delusions by blocking specific chemicals in the brain like serotonin and dopamine.The antipsychotics drugs may be atypical and typical and are available in various forms like injection, tablet, or syrup.
However, high cost of therapy, side effects caused by drugs, and lack of awareness in developing regions may restrain overall market in coming years.
Others segment may include generics and First-Generation Antipsychotics.
The market may be characterized based on distribution channels like rehabilitation centers, hospitals comprising hospital pharmacies, retail pharmacies, clinics, and others that could be explored in forecast period.Globally, North America accounted for the substantial market growth of Schizophrenia Drugs and is estimated to lead the overall market in coming years.
These players are concentrating on inorganic growth to sustain themselves amongst fierce competition.
It is uncommon for schizophrenia to be diagnosed in a person younger than 12 or older than 40.Schizophrenia isn’t caused by just one genetic variation, but a complex interplay of genetics and environmental influences.
Schizophrenia occurs at roughly 10% of people who have a first-degree relative with the disorder, such as a parent or sibling.View Schizophrenia Market ResearchWith medication, psychosocial rehabilitation, and family support, the symptoms of schizophrenia can be reduced.
Typically, a health care provider will prescribe antipsychotics to relieve symptoms of psychosis, such as delusions and hallucinations.
Due to a lack of awareness of having an illness and the serious side effects of medication used to treat schizophrenia, people who have been prescribed them are often hesitant to take them.Schizophrenia is a severe mental disorder that is characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior.
With no cure for schizophrenia, the main goals of schizophrenia treatment include symptom targeting and relapse prevention.What is Schizophrenia Market?The market is expected to grow by factors like an increase in the patient pool, expected entry of emerging products, i.e., such as Roluperidone (MIN-101); Dexmedetomidine (BXCL501); Pimavanserin; Risperidone ISM (DORIA) and other products with deeper penetration in the 7MM markets.Schizophrenia appears suddenly and without warning.
One may start to isolate, begin neglecting the appearance, say peculiar things, and show a general indifference to life.
Schizophrenia is a mental disorder in which thoughts, emotions, and reality are interpreted abnormally.
It can culminate in hallucinations, delusions, and disordered thinking which can impair day-today functioning.
The global Schizophrenia Drugs Market report by Market Research Future (MRFR) contains insights on the condition, treatments, new drugs, and other innovations for the period between 2019 and 2025 (forecast period).Market ScopeThe global Schizophrenia Drugs Forecast is poised to accumulate a significant valuation during the forecast period.
Rising number of cases people being diagnosed with the medical condition, the growing number of the elderly populace, and rise in the research and development of schizophrenia are factors driving market growth.
According to the National Institute of Mental Health, schizophrenia is one of the top 15 causes of disability worldwide.Relaxation of prior authorization (PA) for generic drugs and shift to high quality patient care can impact the market greatly.
The low efficacy of anti-psychotic drugs and the lack of methods of determining their performance has led to the use of dose-response meta-analyses for all placebo clinical trials.
Global Schizophrenia Drugs Market is expected to reach USD 7.9 billion by 2022.
Antipsychotic drugs are mainly prescribed, as they help to control symptoms like disorganized thinking, hallucinations, and delusions by blocking specific chemicals in the brain like serotonin and dopamine.The antipsychotics drugs may be atypical and typical and are available in various forms like injection, tablet, or syrup.
However, high cost of therapy, side effects caused by drugs, and lack of awareness in developing regions may restrain overall market in coming years.
Others segment may include generics and First-Generation Antipsychotics.
The market may be characterized based on distribution channels like rehabilitation centers, hospitals comprising hospital pharmacies, retail pharmacies, clinics, and others that could be explored in forecast period.Globally, North America accounted for the substantial market growth of Schizophrenia Drugs and is estimated to lead the overall market in coming years.
These players are concentrating on inorganic growth to sustain themselves amongst fierce competition.
Schizophrenia Market Research Report: Information by Type (Paranoid Schizophrenia, Hebephrenic Schizophrenia, Catatonic Schizophrenia and Undifferentiated Schizophrenia), Treatment {Second-Generation Antipsychotics [Risperdal (Risperidone), Invega (Paliperidone), Zyprexa (Olanzapine), Geodon (Ziprasidone), Seroquel (Quetiapine), Latuda (Lurasidone)], Third-Generation Antipsychotics and others}, Route of Administration (Oral and Injectables) and Region (Americas, Europe, Asia-Pacific and Middle East & Africa) - Forecast till 2025Market HighlightsThe global Schizophrenia Market is expected to grow at a CAGR of 3.2% during the forecast period 2017-2023.Schizophrenia is a chronic and severe mental disorder that affects the thinking, feeling, and behavior of the person.
People with schizophrenia may be more in imagination world and lost touch with reality.
This is often due to physical illnesses, such as cardiovascular, metabolic and infectious diseases.
Moreover availability of funds and WHO initiative towards developing countries fuel the market in developing region.Regional AnalysisThe Americas dominate the global schizophrenia market owing to the presence of awareness of healthcare, high healthcare spending, and increasing government support for research & development.
Europe holds the second largest share of the global schizophrenia market as result of increasing focus of various government agencies on the treatment of mental illness disease such as schizophrenia.
Moreover, rapidly developing economy, increasing healthcare expenditure, and the government’s initiatives for research & development projected to drive the market in India, Iran, Pakistan, Tanzania, over the forecasted period.
It is uncommon for schizophrenia to be diagnosed in a person younger than 12 or older than 40.Schizophrenia isn’t caused by just one genetic variation, but a complex interplay of genetics and environmental influences.
Schizophrenia occurs at roughly 10% of people who have a first-degree relative with the disorder, such as a parent or sibling.View Schizophrenia Market ResearchWith medication, psychosocial rehabilitation, and family support, the symptoms of schizophrenia can be reduced.
Typically, a health care provider will prescribe antipsychotics to relieve symptoms of psychosis, such as delusions and hallucinations.
Due to a lack of awareness of having an illness and the serious side effects of medication used to treat schizophrenia, people who have been prescribed them are often hesitant to take them.Schizophrenia is a severe mental disorder that is characterized by distortions in thinking, perception, emotions, language, sense of self, and behavior.
With no cure for schizophrenia, the main goals of schizophrenia treatment include symptom targeting and relapse prevention.What is Schizophrenia Market?The market is expected to grow by factors like an increase in the patient pool, expected entry of emerging products, i.e., such as Roluperidone (MIN-101); Dexmedetomidine (BXCL501); Pimavanserin; Risperidone ISM (DORIA) and other products with deeper penetration in the 7MM markets.Schizophrenia appears suddenly and without warning.
One may start to isolate, begin neglecting the appearance, say peculiar things, and show a general indifference to life.
Schizophrenia is a mental disorder in which thoughts, emotions, and reality are interpreted abnormally.
It can culminate in hallucinations, delusions, and disordered thinking which can impair day-today functioning.
The global Schizophrenia Drugs Market report by Market Research Future (MRFR) contains insights on the condition, treatments, new drugs, and other innovations for the period between 2019 and 2025 (forecast period).Market ScopeThe global Schizophrenia Drugs Forecast is poised to accumulate a significant valuation during the forecast period.
Rising number of cases people being diagnosed with the medical condition, the growing number of the elderly populace, and rise in the research and development of schizophrenia are factors driving market growth.
According to the National Institute of Mental Health, schizophrenia is one of the top 15 causes of disability worldwide.Relaxation of prior authorization (PA) for generic drugs and shift to high quality patient care can impact the market greatly.
The low efficacy of anti-psychotic drugs and the lack of methods of determining their performance has led to the use of dose-response meta-analyses for all placebo clinical trials.